The purpose of this study is to see if a new add on (or adjunctive) therapy used in glaucoma surgery improves the success of needle bleb revisions.
To investigate the efficacy of needle bleb revisions with mitomycin C with subconjunctival bevacizumab in promoting both filtering success and favorable bleb morphologic features.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
63
1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
Wills Eye Institute, Glaucoma Service
Philadelphia, Pennsylvania, United States
Intraocular Pressure (IOP)
mmHg (millimeters of mercury)
Time frame: 6 months
Number of Participants With Surgical Success
Surgery was rated as complete success, qualified success or failure. Complete success was defined as 20% (percent) reduction in eye pressure (IOP) without any IOP lowering medications. Qualified success was defined as 20% reduction of IOP with IOP lowering medications. Failure was defined as IOP greater than 21 mmHG (millimeters of mercury), less than 20% IOP reduction or need for additional surgery.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.